Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TAPIR
NCT01940094Phase 3Completed
- Sponsor
- University of Pennsylvania
- Start
- Feb 2014
- Primary completion
- Dec 2024
- Modality
- Orthosteric Ligands
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of prednisone in granulomatosis with polyangiitis (GPA) (2 arms), sponsored by University of Pennsylvania. Primary endpoint: Prednisone Dose Increase for Disease Relapse at 6 months. Started Feb 2014; status: completed.
02
Drugs
prednisone
03
Conditions
granulomatosis with polyangiitis (GPA)
Beyond the preview
Go deeper on NCT01940094.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01940094.